sharetrader
Page 3 of 28 FirstFirst 123456713 ... LastLast
Results 31 to 45 of 420
  1. #31
    AWOL
    Join Date
    Sep 2012
    Location
    Vacation
    Posts
    2,428

    Default

    Why stop there? Clare Capital I think it was gave them 22.00. Even ballieu gave them a top of 27c

  2. #32
    Member penn's Avatar
    Join Date
    Oct 2014
    Posts
    257

    Default

    I have been pondering the reason that the share price has not rocketed on the recent good news, there is quite an over-hang from the 2013 purchase.
    "As well as the cash payment in May 2013 to purchase Advangen, CDY issued 55,737,624 shares at a nominal issue price of 5 cents each to 12 Advangen Inc. shareholders, thereby acquiring 100% of the shares of that company. "
    If I was one of those 12, I would have been selling on a regular basis to buy fresh hot Sake.
    However Eighteen months is a long time and soon -very very soon those shares will be ours Mwahahhaa. (sorry - had too much Sake)

  3. #33
    AWOL
    Join Date
    Sep 2012
    Location
    Vacation
    Posts
    2,428

    Default

    Quote Originally Posted by penn View Post
    I have been pondering the reason that the share price has not rocketed on the recent good news, there is quite an over-hang from the 2013 purchase.
    "As well as the cash payment in May 2013 to purchase Advangen, CDY issued 55,737,624 shares at a nominal issue price of 5 cents each to 12 Advangen Inc. shareholders, thereby acquiring 100% of the shares of that company. "
    If I was one of those 12, I would have been selling on a regular basis to buy fresh hot Sake.
    However Eighteen months is a long time and soon -very very soon those shares will be ours Mwahahhaa. (sorry - had too much Sake)
    Once the great unknown amount of the upfront payment from Zoetis is revealed things might get cracking.
    It seems the Aussie market is lagging behind in biotech stocks overall acccording to HC.
    There is an interesting flow chart on HC that shows the relationships cellmid has with all the different products. Seems they have seven sources of income so far.
    Think you will find it in the senile plaque thread- one of traes posts.
    Last edited by Minerbarejet; 07-12-2014 at 08:36 AM.

  4. #34
    Member penn's Avatar
    Join Date
    Oct 2014
    Posts
    257

    Default

    Ahh yes, found it, thanks, a very nice piece of work. I think I shall print off a few hundred copies and make them into my Christmas cards.

    http://hotcopper.com.au/threads/midk...9#.VIUo4Geo69I

    Folk on here will have to sign in to HC to view it,

  5. #35
    AWOL
    Join Date
    Sep 2012
    Location
    Vacation
    Posts
    2,428

    Default

    You must have a lot of mates.
    Are they Penn friends?

  6. #36
    The past is practise. Vaygor1's Avatar
    Join Date
    Dec 2012
    Location
    Northland
    Posts
    925

    Default

    Quote Originally Posted by Minerbarejet View Post
    You must have a lot of mates.
    Are they Penn friends?
    Pennding questions...
    Would a few hundred copies happenn to be expennsive? Would they openn them?

  7. #37
    Member penn's Avatar
    Join Date
    Oct 2014
    Posts
    257

    Default

    Be very careful - The PENN is mightier than the S word.

  8. #38
    Member penn's Avatar
    Join Date
    Oct 2014
    Posts
    257

    Default

    Trading halt regarding capital raising. Doh!

  9. #39
    AWOL
    Join Date
    Sep 2012
    Location
    Vacation
    Posts
    2,428

    Default

    Quote Originally Posted by penn View Post
    Trading halt regarding capital raising. Doh!
    Not quite, trading halt regarding proposal for capital raising.
    Three months is up from original proposal date Sept 10th set at AGM
    Could still cancel which would do things as well


    Dont press the pennic button just yet
    Last edited by Minerbarejet; 11-12-2014 at 02:12 PM.

  10. #40
    Member penn's Avatar
    Join Date
    Oct 2014
    Posts
    257

    Default

    I had buy order in today for some of the options at 1c ( did not get filled) but someone has a buy in for 1 option at 1.2c! Manpulation? or something else?

  11. #41
    AWOL
    Join Date
    Sep 2012
    Location
    Vacation
    Posts
    2,428

    Default

    Quote Originally Posted by penn View Post
    I had buy order in today for some of the options at 1c ( did not get filled) but someone has a buy in for 1 option at 1.2c! Manpulation? or something else?
    Have a look at this mornings premarket on cdy. Buy at 29 nearly takes out sell at 27. If that happens then there will just be a few left which will look as if someone is trying to sell a small amount.
    On that note there are twice as many roughly shares wanted as available and the price has returned to precap raising ann level.
    The millions wanted at 25 24 23 22 were there to scoop up the expected effect of the cap raising. This did not occur, or hasn't so far,
    and as a guess Id say it was because of a much lessened dilution than expected and also in a roundabout fashion a hint that the Zoetis deal upfront may be actually quite good.
    Plus another patent issued for Midkine

  12. #42
    Member penn's Avatar
    Join Date
    Oct 2014
    Posts
    257

    Default

    I see. Thanks for that. Yes does look as though the Zoetis up-front payment could be in the $400,000-$4,000,000 range thereby reducing the ammount required for the CR. Still world events oft have a bigger impact.

  13. #43
    Member penn's Avatar
    Join Date
    Oct 2014
    Posts
    257

    Default

    Quote Originally Posted by Minerbarejet View Post
    Why stop there? Clare Capital I think it was gave them 22.00. Even ballieu gave them a top of 27c
    If I am finding it hard to sleep I go here.

    http://www.valuecruncher.com/companies/13848

  14. #44
    Member penn's Avatar
    Join Date
    Oct 2014
    Posts
    257

    Default Australian patent granted for use of midkine for hair growth

    Todays news is huge for a company with such a small M Cap.

    AUSTRALIAN PATENT GRANTED FOR USE OF MIDKINE FOR HAIR GROWTH

    •  Patent for use of midkine to prevent and treat hair loss and to promote and enhance hair growth issued
    •  Comprehensive protection over midkine and related protein pleiotrophin with long patent life (to 2031)
    •  Major boosts to Cellmid’s hair growth asset portfolio
    • Woop Woop! (sorry that was not meant to be a ramp)

  15. #45
    AWOL
    Join Date
    Sep 2012
    Location
    Vacation
    Posts
    2,428

    Default

    Followed by:
    USA PATENT FOR MIDKINE TO TREAT HEART FAILURE
    · USA patent granted for use of midkine to treat heart failure
    · Patent coverage for midkine as a chronic treatment for cardiac
    disease
    · Global patent family already in force in Europe and Japan
    SYDNEY, Wednesday, 21 January 2015: Cellmid Limited (ASX: CDY) advises that the
    USA Patent Office has granted the Company’s patent application 11/720,983
    entitled " Composition for treating or preventing myocardial disorder or heart failure".
    The granted claims cover the use of midkine (MK) as a treatment for heart failure
    which commonly follows non-fatal heart attacks.
    In published studies using in vivo animal models, MK treatment following heart attack
    potently promotes new blood vessel growth in the affected tissue (angiogenesis),
    limits cardiac dysfuntion, promotes ventricular tissue repair and increases long term
    survival rates. Significantly, MK is effective even where treatment initiation is delayed
    for weeks after infarct.
    “This patent reinforces Cellmid’s comprehensive intellectual property position in using
    MK therapeutically”, said Cellmid CEO Maria Halasz. “Through several global patent
    families Cellmid’s patent coverage now extends across a number of related
    mechanisms of action” she added.
    “Midkine could become an important agent in the treatment of heart failure” said
    Head of Product Development, Darren Jones. “In an acute setting MK prevents
    cardiomyocyte death at the time of the heart attack. In the longer term MK
    promotes beneficial fibrosis and angiogenesis in the cardiac muscle in the weeks
    following a heart attack” he added.
    Cellmid’s equivalent patents have already been granted in Europe and Japan.
    Cellmid holds the most significant intellectual property assets related to MK
    worldwide. Cellmid’s patent portfolio currently includes 87 patents in 20 patent
    families, which cover the use of MK and anti-MK agents for therapeutic purposes in a
    number of diseases, as well as the use of MK as a diagnostic marker in cancer and
    other disorders.

    More good news for CDY

    Veterinary drug giant Zoetis ($ZTS) also drew a crowd at JP Morgan. The company has been under pressure from Pershing Square's Bill Ackman, an activist investor who bought a boatload of shares last year, reportedly with the intention of encouraging the company to put itself up for sale. During a Q&A session after Zoetis' Wednesday presentation, analysts pressed executives for details about their plans to maintain Zoetis as a viable standalone company.
    Among the topics was Zoetis' acquisition strategy. In November, the company paid $255 million to acquire Abbott's ($ABT) animal-health assets, which included a suite of surgical tool. Zoetis would like to find more such opportunities--"small or medium" transactions that fill holes in the company's product portfolio, said executive vice president Kristin Peck during the Q&A.
    Chief Financial Officer Paul Herendeen added that Zoetis "would lever up, potentially aggressively" if the right deal came along.
    But Ackman has griped about Zoetis' cost structure, which was also a topic of concern during the Q&A. When asked about opportunities to improve efficiency, Herendeen said the company had an operating spend of $1.8 billion in 2013, minus cost of goods sold. About half of that was sales and marketing expenses, he said, including the costs of maintaining the company's sales force of 3,500.
    The greatest opportunities for cost-cutting, Herendeen said, may be in general and administrative expenses, which were largely impacted by the company's spinoff from Pfizer ($PFE). Zoeits is currently working to streamline its technology platforms, which should increase efficiency and bring costs down, he indicated. "I would say that our current level of G&A spend is above what you should expect for a company of our scale and of our global footprint. And that's because we're just putting it in place," Herendeen said.

    Zoetis is the outfit that CDY signed an agreement for the use of midkine in treating animals.

Bookmarks

Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts
  •